699P Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1)
暂无分享,去创建一个
M. Galsky | S. Srinivas | A. Balar | J. Rosenberg | B. Nelson | A. Necchi | A. Drakaki | Y. Loriot | J. Hoffman-Censits | M. V. D. Heijden | X. Shen | A. Javery | H. X. Huang